OncoMatch/Clinical Trials/NCT07782164
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Is NCT07782164 recruiting? Yes, currently enrolling (Sep 2026).
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Renal Cell Carcinoma
Urothelial Carcinoma
Cervical Cancer
Prostate Cancer
Ovarian Cancer
Disease stage
Metastatic disease required
Lung Cancer (Including Metastatic Cancer)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07782164 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages